- Market Capitalization, $K 515,595
- Shares Outstanding, K 29,547
- Annual Sales, $ 312,690 K
- Annual Income, $ -274,880 K
- 60-Month Beta 1.42
- Price/Sales 1.57
- Price/Cash Flow N/A
- Price/Book N/A
|Period||Period Low||Period High||Performance|
| || |
+0.33 (+1.98%)since 12/20/21
| || |
-0.21 (-1.22%)since 10/20/21
| || |
-11.45 (-40.25%)since 01/20/21
This could be a very exciting year for these drugmakers.
Intellia (NTLA) inks a licensing and collaboration deal with Kyverna Therapeutics for developing an allogeneic CAR T-cell therapy for autoimmune diseases.
Study remains ongoing; top-line data anticipated in Q1 2022 versus near the end of the year...
Intercept (ICPT) withdraws its application seeking approval for OCA for the treatment of liver fibrosis due to nonalcoholic steatohepatitis in the EU. Resultantly, the stock declines.
Investors need to pay close attention to Intercept (ICPT) stock based on the movements in the options market lately.
NEW YORK, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), a biopharmaceutical company focused on the development and...
Palm Beach, FL –November 16, 2021 – FinancialNewsMedia.com News Commentary – The COVID-19 pandemic has affected the healthcare systems globally and also has a significant impact on the cancer therapy...
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Intercept Pharmaceuticals Inc , where a total volume of 10,380 contracts has been traded...
Analysis compares findings from the long-term safety extension of the Phase 3 POISE trial to PBC natural history data from the Global PBC and UK-PBC...
NEW YORK, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and...
|3rd Resistance Point||19.02|
|2nd Resistance Point||18.60|
|1st Resistance Point||17.80|
|1st Support Level||16.57|
|2nd Support Level||16.15|
|3rd Support Level||15.35|